David B. Zhen, MD, discusses the results of the phase 3 CheckMate 649 trial in patients with advanced gastric cancer, ...

Predicting mortality in upper gastrointestinal tract cancer using long short-term memory neural networks. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This ...

Among patients with advanced gastric and GEJ cancer, or esophageal adenocarcinoma, treatment with first-line Opdivo and chemo demonstrated deep responses.

Basketball legend and Hall of Famer Dwayne Wade recently shared that part of his right kidney was removed in 2023 after ...

The advantage of these drugs is they kill cancer cells throughout your body. One downside is the side effects they can cause -- including upset stomach. In the past, people who got chemo had to ...

The addition of lenvatinib and pembrolizumab to chemotherapy did not extend OS for certain patients with advanced ...

Leap Therapeutics (LPTX) lost 63% after announcing it will not run a Phase 3 trial for its lead asset sirexatamab in gastric ...

The phase 3 CheckMate 649 trial showed that nivolumab plus chemotherapy significantly improved long-term overall survival in ...

Shares of Leap Therapeutics (NASDAQ:LPTX) tumbled 64% in pre-open trading Tuesday as the company announced that its ...

Q-TWiST analysis of pembrolizumab plus trastuzumab and chemotherapy for patients with metastatic HER2-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma in the KEYNOTE-811 trial.

Leap Therapeutics, Inc.'s DKN-01 trial results show mixed outcomes in cancer treatment, prompting potential future funding ...